Back

Reversible P2Y12 inhibitor versus irreversible P2Y12 inhibitor in ACS patients undergoing PCI (the acute coronary syndrome israeli survey (ACSIS)

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Congress committee e-posters choice in CAD/ACS/ACC Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Bethlehem Mengesha

University of Ottawa Heart Institute, Ottawa (Canada)

28 More presentations in this session

Presentation thumbnail
Post-discharge major bleeding, myocardial infarction and mortality risk after coronary artery bypass grafting: A nationwide cohort study from the SWEDEHEART registry
Doctor E. Bjoerklund (Gothenburg, SE)
Abstract Slides
Presentation thumbnail
Trends in cardiovascular mortality of cancer patients in the US over two decades 1999-2019
Doctor O. Kobo (Hadera, IL)
Abstract Slides
Presentation thumbnail
Underuse of reperfusiontherapy in STEMI with cardiogenic shock. Results of the EORP ACVC EAPCI STEMI registry of the ESC.
Professor U. Zeymer (Ludwigshafen, DE)
Abstract Slides
Presentation thumbnail
The effect of immediate coronary angiography after cardiac arrest without ST-segment elevation on left ventricular function. A sub-study of the COACT randomised trial
Doctor J. Lemkes (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Comparison of risk prediction models in infarct-related cardiogenic shock
Doctor A. Freund (Leipzig, DE)
Abstract Slides

Access the full session

Session thumbnail
Congress committee e-posters choice in CAD/ACS/ACC

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy
31 August 2019
thumbnail
Congress Session
Acute coronary syndromes and high-risk PCI: state of the art
26 August 2023
thumbnail
Congress Presentation
Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis
1 September 2020
thumbnail
Congress Presentation
Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources